Search Results
Jan 21, 2026, 18:30 ET MILESEEY Golf Unveils GeneSonic Pro, the World's First Golf Speaker with Detachable GPS Handheld, at PGA Show 2026
GeneSonic Pro delivers up to three full 18-hole rounds or 15 hours of continuous playback on a single charge. The device supports 30W PD fast charging and can function as an emergency power source for mobile devices. Built for all-weather performance, GeneSonic Pro features an IP67-rated
More news about: Mileseey Technology (US) Inc.
Jan 21, 2026, 07:30 ET Keenova Marks 100K Peyronie's Disease Patients--a Major Milestone for an Often-Stigmatized Men's Health Condition
Diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help.3* As of January 2026, 100,020 men have been prescribed XIAFLEX for PD. Calculations and estimations based on transactions for XIAFLEX for PD from January 1, 2014 to January 13, 2026.1IMPORTANT
More news about: Keenova Therapeutics
Jan 20, 2026, 19:15 ET Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
recognized as a key driver of neuroinflammation, contributing to the pathology of multiple neurodegenerative diseases, including Parkinson's disease (PD) and Alzheimer's disease (AD). While NLRP3 inhibition holds significant therapeutic promise, there are currently no approved therapies that directly
More news about: Insilico Medicine
Jan 20, 2026, 15:29 ET The Michael J. Fox Foundation Launches 2026 "Parkinson's IQ + You" Event Series to Educate, Empower and Connect People and Families Living with Parkinson's Disease
Parkinson's IQ + You national event series, traveling across the United States to educate and empower people and families living with Parkinson's disease (PD). As part of the Foundation's mission to accelerate research breakthroughs in Parkinson's disease, MJFF hosts the series to equip people with Parkinson's
More news about: The Michael J. Fox Foundation for Parkinson's Research
Jan 20, 2026, 13:53 ET Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies
engagement confirmed (reduced NLRP3, ASC, cleaved caspase-1, IL-1β, IL-18) in the brain in two models: a PD prevention model (i.e., α-synuclein pre-formed fibril model) and, critically, in a PD therapeutic model initiated after symptom onset (i.e., PLP-α-synuclein transgenic model).Dr
More news about: Olatec Therapeutics, Inc.
Jan 20, 2026, 08:37 ET ENQUÊTE MONDIALE DU PD : LES DIRIGEANTS COMMERCIAUX SONT OPTIMISTES QUANT À 2026 MALGRÉ LA MONTÉE DES BARRIÈRES
content:https://www.prnewswire.com/news-releases/enquete-mondiale-du-pd--les-dirigeants-commerciaux-sont-optimistes-quant-a-2026-malgre-la-montee-des-barrieres-302665413.html
More news about: DP World
Jan 20, 2026, 02:55 ET Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology
technology, for the development and commercialization of a subcutaneous formulation of dostarlimab, a programmed death receptor-1 (PD-1) blocking antibody. Alteogen will receive an upfront payment of US$20 million and is eligible to receive milestone payments up to US$265 million
More news about: Alteogen Inc.
Jan 19, 2026, 17:00 ET Power Metallic Reports Lion Zone Recoveries of 98.9% Copper, 93.9% Palladium, 96.8% Platinum, 85% Gold and 88.9% Silver from Initial Metallurgical Results as Reported by SGS Canada Inc.
Locked-cycle flotation testing produced a high-grade concentrate containing 25.8% Cu, 1.2% Ni, 4.83 g/t Au, 41.4 g/t Pd, 23.4 g/t Pt, and 159 g/t Ag, with robust recoveries for Cu (98.9%), Pd (93.9%), Pt (96.8%), and Ag (88.9%).These results suggest potential opportunities for
More news about: Power Metallic Mines Inc.
Jan 19, 2026, 08:00 ET FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene's NouvNeu001, Making It the World's First iPSC Therapy with Both FTD and RMAT Recognitions
granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson's disease (PD). This milestone makes NouvNeu001 the first allogeneic iPSC-derived cell therapy globally to hold both FDA Fast Track Designation (FTD) and RMAT
More news about: iRegene Therapeutics Co., Ltd
Jan 19, 2026, 02:00 ET Henlius präsentiert auf der JPM 2026 die Strategie „Globalisation 2.0" sowie einen mittel- bis langfristigen Innovationsfahrplan
wichtigsten Innovationskandidaten im Jahr 2026 vor, darunter Serplulimab (Handelsname: Hetronifly® in Europa), ein Anti-PD-1-MAb; HLX22, ein neuartiger Epitop-Anti-HER2-MAb; HLX43, ein PD-L1-ADC; und HLX07, ein Anti-EGFR-MAb.Derzeit umfasst das präklinische Portfolio des Unternehmens mehrere molekulare
More news about: Henlius
Jan 19, 2026, 02:00 ET Henlius presenta su estrategia "Globalización 2.0" y su plan de innovación a medio y largo plazo en JPM 2026
sus activos de innovación clave en 2026, incluidos serplulimab (nombre comercial: Hetronifly® en Europa), un mAb anti-PD-1; HLX22, un nuevo mAb anti-HER2 de epítopo; HLX43, un ADC PD-L1; y HLX07, un mAb anti-EGFR.Actualmente, la cartera de activos preclínicos de la Compañía abarca múltiples modalidades
More news about: Henlius
Jan 19, 2026, 02:00 ET Henlius présente sa stratégie « Globalisation 2.0 » et son plan d'innovation à moyen et long terme lors de la conférence JPM 2026
principaux actifs innovants en 2026, notamment le serplulimab (nom commercial : Hetronifly® en Europe), un AcM anti-PD-1 ; le HLX22, un AcM anti-HER2 à nouvel épitope ; le HLX43, un ADC PD-L1 ; et le HLX07, un AcM anti-EGFR.Actuellement, le portefeuille d'actifs précliniques de la société couvre
More news about: Henlius
Jan 16, 2026, 08:00 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
drug candidates.Key early-stage assets include:HLX37: PD-L1 × VEGF bispecific antibody developed based on the immune checkpoint inhibitor platform. It demonstrates high PD-L1 binding affinity and achieves higher tumour microenvironment (TME) enrichment vs. combination
More news about: Henlius
Jan 16, 2026, 08:00 ET Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
mFOLFOX6 chemotherapy across wide ranges of PD-L1 and CLDN18.2 expression levels."The dose expansion data reinforce the strong signals we observed in dose escalation. The efficacy is clear at 8 mg/kg, with robust ORRs, including in subgroups defined by low PD-L1 and/or CLDN18.2 expression," said Phillip
More news about: Equity Insider
Jan 16, 2026, 07:30 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
development plans for its key innovation assets in 2026, including serplulimab (trade name: Hetronifly® in Europe), an anti-PD-1 mAb; HLX22, a novel epitope anti-HER2 mAb; HLX43, a PD-L1 ADC; and HLX07, an anti-EGFR mAb.At present, the Company's preclinical asset portfolio spans multiple molecular
More news about: Henlius
Jan 15, 2026, 20:00 ET Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
ADCs and Proprietary TCEsATG-125 (B7-H3 × PD-L1 bispecific ADC): ATG-125 is an "IO+ADC " dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation
More news about: Antengene Corporation Limited
Jan 15, 2026, 19:00 ET JPM 2026 | 科倫博泰CEO葛均友博士全面展示公司創新成果及未來發展戰略
項適應症，包括二線及以上三陰性乳腺癌、二線 / 三線 EGFR 突變 NSCLC；HER2 ADC 博度曲妥珠單抗於去年獲批二線及以上 HER2 陽性乳腺癌，成為該適應症首款上市的國產 HER2 ADC；此外，用於治療 RAS 野生型結直腸癌的 EGFR 單抗西妥昔單抗 N01（達泰萊®）以及用於治療鼻咽癌的 PD-L1 單抗塔戈利單抗（科泰萊®）均實現了商業化；另有一款小分子 RET 抑制劑 A400 預計年內獲批上市，屆時將在國內形成 5 款商業化產品組合。目前，公司已有 3 款商業化產品共 5 項適應症納入國家醫保，進一步惠及廣大腫瘤患者。深耕國內市場的同時，科倫博泰也在積極拓展海外版圖，已與默沙東（MSD）、Ellipses、Windward
More news about: 科倫博泰
Jan 15, 2026, 14:07 ET Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
Transplantation (HSCT) before or after being treated with a PD-1/PDL1 blocking antibody. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1–blocking antibody prior to or after an allogeneic HSCT.Embryo-Fetal
More news about: Sun Pharma
Jan 15, 2026, 13:30 ET Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference
for this indication. Furthermore, the anti-EGFR monoclonal antibody Cetuximab N01 (达泰莱®) for RAS wild-type colorectal cancer and the anti-PD-L1 monoclonal antibody tagitanlimab (科泰莱®) for nasopharyngeal carcinoma have been launched. Another small-molecule RET inhibitor A400 is expected
More news about: Kelun-Biotech
Jan 13, 2026, 22:54 ET Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
against a PD-1 inhibitor plus chemotherapy for the first-line (1L) treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS <5 (a propensity-matched, retrospective cohort study). The study results showed that the cadonilimab regimen, compared to the PD-1 monoclonal
More news about: Akeso, Inc.
Jan 13, 2026, 12:33 ET Adimab Records Another Year of Double-Digit Clinical Program Growth
CRSwNP.Other commercial products containing molecules from Adimab include:Innovent's TYVYT® (sintilimab injection), a PD1 program approved in China for the treatment of multiple cancers.Innovent's SINTBILO® (tafolecimab injection), a PCSK9 program approved
More news about: Adimab, LLC
Jan 13, 2026, 07:30 ET Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
double-blind, placebo-controlled, multiple ascending dose (MAD) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of repeated intrathecal injections of RAG-17 in patients with SOD1 mutations. The participating sites include
More news about: Ractigen Therapeutics
Jan 13, 2026, 04:33 ET aulumu Showcases High-Performance Design Philosophy at CES 2026 with G09 and M10
health. Its dual-sided magnetic design ensures secure MagSafe attachment, adding convenience on the go. Supporting a wide range of protocols, including PD, AFC, SCP, FCP, QC2.0, QC3.0, and Qi2, the M10 adapts to diverse devices and standards. Ideal for business travel, daily commutes, and extended trips,
More news about: aulumu
Jan 12, 2026, 12:15 ET Solution Tree Launches New Podcast Beyond the Pages with Solution Tree, Hosted by Rob J. Meyer, EdD
essential challenges. Solution Tree has a catalog of more than 600 titles, along with hundreds of videos and online courses, and is the creator of Global PD Teams and Avanti, online learning platforms that facilitate the work of teachers and educators. Follow @SolutionTree on Facebook and Instagram. Learn
More news about: Solution Tree
Jan 12, 2026, 11:15 ET Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
conjugates (ADCs) in oncology Phase 1/2 study evaluating BHV-1510 (Trop2 ADC) as monotherapy and in combination with Regeneron's anti-PD-1 monoclonal antibody cemiplimab shows continued clinical activity with confirmed responses and a differentiated safety profile in the ongoing study.Endometrial
More news about: Biohaven Ltd.